BACKGROUND: ASCOT-BPLA study demonstrates that in hypertensive subjects, atenolol+bendroflumethiazide therapy is associated with higher incidence of adverse cardiovascular outcomes and developing diabetes than an amlodipine+perindopril regimen. This is not explained by changes in blood pressure alone. We hypothesized that distinct vascular and metabolic effects of anti-hypertensive drugs may explain these differential effects. METHODS: Either placebo or one class of anti-hypertensive drug (atenolol 100 mg, amlodipine 10 mg, hydrochlorothiazide 50 mg, ramipril 10 mg, or candesartan 16 mg) was given daily during 8 weeks to 31 patients in each of 6 arms of a randomized, single-blind, placebo-controlled, parallel study. RESULTS:Atenolol, amlodipine, and candesartan therapies significantly reduced systolic blood pressure when compared with ramipril (P<0.05 by ANOVA). Atenolol and thiazide therapies increased triglycerides levels greater than ramipril or candesartan (P=0.005 by ANOVA). Amlodipine significantly increased HDL cholesterol levels greater than atenolol (P=0.011 by ANOVA). Ramipril and candesartan therapies improved FMD and increased adiponectin levels and insulin sensitivity to a greater extent than atenolol or thiazide therapies (P<0.001 and P<0.015 by ANOVA). Amlodipine therapy increased adiponectin levels greater than atenolol therapy (P<0.05 by ANOVA). Ramipril, candesartan, and amlodipine therapies significantly decreased leptin levels to a greater extent when compared with atenolol or thiazide therapies (P<0.001 by ANOVA). Amlodipine therapies significantly decreased resistin levels greater than ramipril or candesartan therapies (P=0.001 by ANOVA). CONCLUSIONS: We observed differential effects of anti-hypertensive drugs on endothelial dysfunction and plasma adipocytokines. Copyright 2008 Elsevier Ireland Ltd. All rights reserved.
RCT Entities:
BACKGROUND: ASCOT-BPLA study demonstrates that in hypertensive subjects, atenolol+bendroflumethiazide therapy is associated with higher incidence of adverse cardiovascular outcomes and developing diabetes than an amlodipine+perindopril regimen. This is not explained by changes in blood pressure alone. We hypothesized that distinct vascular and metabolic effects of anti-hypertensive drugs may explain these differential effects. METHODS: Either placebo or one class of anti-hypertensive drug (atenolol 100 mg, amlodipine 10 mg, hydrochlorothiazide 50 mg, ramipril 10 mg, or candesartan 16 mg) was given daily during 8 weeks to 31 patients in each of 6 arms of a randomized, single-blind, placebo-controlled, parallel study. RESULTS:Atenolol, amlodipine, and candesartan therapies significantly reduced systolic blood pressure when compared with ramipril (P<0.05 by ANOVA). Atenolol and thiazide therapies increased triglycerides levels greater than ramipril or candesartan (P=0.005 by ANOVA). Amlodipine significantly increased HDL cholesterol levels greater than atenolol (P=0.011 by ANOVA). Ramipril and candesartan therapies improved FMD and increased adiponectin levels and insulin sensitivity to a greater extent than atenolol or thiazide therapies (P<0.001 and P<0.015 by ANOVA). Amlodipine therapy increased adiponectin levels greater than atenolol therapy (P<0.05 by ANOVA). Ramipril, candesartan, and amlodipine therapies significantly decreased leptin levels to a greater extent when compared with atenolol or thiazide therapies (P<0.001 by ANOVA). Amlodipine therapies significantly decreased resistin levels greater than ramipril or candesartan therapies (P=0.001 by ANOVA). CONCLUSIONS: We observed differential effects of anti-hypertensive drugs on endothelial dysfunction and plasma adipocytokines. Copyright 2008 Elsevier Ireland Ltd. All rights reserved.
Authors: M de Courten; P Ferrari; M Schneider; L Böhlen; S Shaw; W Riesen; G Heynen; P Weidmann Journal: Eur J Clin Pharmacol Date: 1993 Impact factor: 2.953
Authors: Byung-Soo Youn; Kang-Yeol Yu; Hong Je Park; Nam Seok Lee; Sung Shik Min; Moon Yeon Youn; Young Min Cho; Young Joo Park; Seong Yeon Kim; Hong Kyu Lee; Kyong Soo Park Journal: J Clin Endocrinol Metab Date: 2004-01 Impact factor: 5.958
Authors: Mona Elbadawi-Sidhu; Rebecca A Baillie; Hongjie Zhu; Yii-Der Ida Chen; Mark O Goodarzi; Jerome I Rotter; Ronald M Krauss; Oliver Fiehn; Rima Kaddurah-Daouk Journal: Metabolomics Date: 2016-12-23 Impact factor: 4.290
Authors: A R Sabbatini; A P Faria; N R Barbaro; W M Gordo; R G P Modolo; C Pinho; V Fontana; H Moreno Journal: J Hum Hypertens Date: 2013-11-28 Impact factor: 3.012
Authors: Joel L Ramirez; Sukaynah A Khetani; Greg J Zahner; Kimberly A Spaulding; Melinda S Schaller; Warren J Gasper; Nancy K Hills; Anne L Schafer; S Marlene Grenon Journal: J Vasc Surg Date: 2018-10-03 Impact factor: 4.268